Bovine High-Mountain Disease Market

Bovine High-Mountain Disease Market Overview

Global Bovine high-mountain disease demand is projected to be valued at US$ 4.32 Billion in 2022, forecast to grow at a CAGR of 5.25% to be valued at US$ 7.2 Billion from 2022 to 2032. Growth is attributed to the rising demand for renovation projects and development in residential and commercial construction.

Bovine high-mountain disease (BHMD) is also known as brisket disease which causes significant death loss, especially in calves. The bovine high-mountain disease is right heart failure which is generally caused due to hypoxic pulmonary hypertension at high altitudes. The bovine high-mountain disease is found in cattle at elevations over 7,000 feet and affects cattle of all ages and breeds.

Higher elevations directly increase the incidence rate of bovine respiratory disease. The bovine high-mountain disease is generally associated with factors like altitude, physiologic, genetic, and environmental. It is also said that bovine high-mountain disease could be associated with mortality and morbidity associated with bovine respiratory disease (BRD). Some of the symptoms associated with the bovine high-mountain disease are weakness, collapse, diarrhea, bulging eyes, swelling due to edema of the limbs, and others.

Which are Some Prominent Drivers Spearheading Bovine high-mountain diseases Market Growth?

The rising incidence of congestive heart failure in cattle is considered a major driving factor in driving the growth of the global bovine high-mountain disease market. Furthermore, the rising prevalence of respiratory disease, lung abscesses, migrating parasitic larvae and lungworms, and genetic susceptibility further contribute to boosting the growth of the global bovine high-mountain disease drug market.

A susceptible animal is generally more prone to develop bovine high-mountain disease if any of the above parameters are present.

What are the Challenges Faced by the Bovine High-Mountain Disease Industry?

There are also other diseases (like congenital heart disease, parasites, etc.) that are very similar to the bovine high-mountain disease which often causes difficulties in differentiating them. Thus, the lack of information about the bovine high-mountain disease is expected to hamper the growth of the global bovine high-mountain disease market.

Generally, a pulmonary artery pressure (PAP) test is conducted in order to determine the bovine high-mountain disease. The high cost related to the treatment of bovine high-mountain disease is also expected to deter the growth of the global bovine high-mountain disease market.

Why is Asia-Pacific Emerging as an Opportunistic Bovine high-mountain disease Market?

APAC region has witnessed a tremendous increment in the bovine high-mountain disease in the past 2 to 3 decades. Numerous range plants, both browse and non-browse types, have been linked with augmented incidence of BHMD, but only locoweed has been experimentally shown to induce the disease.

Moreover, owing to poor health facilities in the hilly areas, the cattle are unable to get proper treatment and oxygen support due to high altitude. Governments of several countries are setting up veterinary hospitals in hilly residential areas to provide quick medical support, thereby, fostering the bovine high-mountain disease drug market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is Europe Contributing to the Growth of the Bovine high-mountain disease Market?

Western Europe is anticipated to register the second most market share in the global bovine high-mountain disease market due to the presence of established manufacturers in the region. The Latin American bovine high-mountain disease market is expected to grow at a significant growth rate over the forecast period.

Why does North America Hold a Significant Share in the Bovine high-mountain disease Market?

North American bovine high-mountain disease market is anticipated to register a maximum market share in the global bovine high-mountain disease market. The bovine high-mountain disease is very common in cattle raised on ranches at high altitudes (more than 5,000 feet) in Colorado, Wyoming, New Mexico, and Utah. It also affects cattle in mountainous ranges of the world, most commonly at elevations >6,500 ft (1,981 m) in western Canada and South America. BHMD affects cattle of all ages and breeds, but not necessarily equally.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Market Competition

Some of the key participants present in the global demand of the Bovine high-mountain disease market include Zoetis, Inc., Bayer AG, Eli Lilly and Company (Elanco), Dechra Pharmaceuticals, Merck & Co., Inc, and others.

• In March 2021, Zoetis Inc. announced its long-term sustainability goals, which were built on the company’s purpose to nurture the world and humankind by advancing care for animals. Under the banner Driven to Care, Zoetis brings to life its specific commitments to Communities, Animals, and the Planet, including support of 10 of the 17 United Nations’ Sustainable Development Goals (SDGs). 

Report Scope

Key Segments Profiled in the Bovine High-Mountain Disease Industry Survey

By Drug Class:

• Bovine High-Mountain Disease Diuretics
• Bovine High-Mountain Disease Antibiotics
• Bovine High-Mountain Disease Appetite Stimulators
• Other Bovine High-Mountain Disease Drugs

By Distribution Channel:

• Bovine High-Mountain Disease Drugs Sales via Veterinary Hospitals
• Bovine High-Mountain Disease Drugs Sales via Veterinary Clinics
• Bovine High-Mountain Disease Drugs Sales via Veterinary Pharmaceutical Stores
• Bovine High-Mountain Disease Drugs Sales via Other Distribution Channels

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific excluding China & Japan
• China
• Japan
• Middle East and Africa